No abstract

No abstract

Highlights. The results of primary prevention of atrial fibrillation by using antiarrhythmic drug therapy and modulated kinesitherapy in patients with metabolic syndrome with premature atrial complexes are presented.A significant decrease in the development of the disease was revealed in patients with metabolic syndrome and risk of atrial fibrillation within a year after the examination with the help of pharmacological antiarrhythmic therapy of atrial ectopia and modulated kinesotherapy as primary prevention in comparison with therapy aimed at correcting blood pressure, glucose and blood lipids.Aim. To assess the possibility of using antiarrhythmic drug therapy (DT) and modulated kinesitherapy (MK)  in patients with metabolic syndrome (MS) and premature atrial complexes (PAC) as the primary prevention of atrial fibrillation (AF).Methods. 426 MS patients with PAC aged from 58 to 72 years (mean 66.4±0.7 years) were included in the study. All patients had a high probability of developing primary AF within 1 year after the enrollment. Antiarrhythmic DT with class I–III  drugs was used as the primary prophylaxis of AF in 149 (34.97%) patients, MK  – in 121 (28.40%), the correction of blood pressure, glucose and blood lipids – in 156 (36.63%). All patients were followed up for one year and the end point of observation was the maintenance of sinus rhythm or AF registration.Results. Various clinical forms of AF were recorded in 26.45, 31.54% and 95.51% of patients with MS during primary prevention with the help of pharmacological AAT, UA and correction of its potentially modifiable components (arterial pressure, glucose and blood lipids), respectively, during the year after the examination.Conclusion. The use of both antiarrhythmic DT of I–III classes, and MК as a primary prophylaxis of AF in patients with MS with PAC and the risk of AF development within one year after the first examination made it possible to reduce the frequency of the arrhythmia by the correction of blood pressure, glucose and blood lipids.

No abstract

No abstract